In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Lipid abnormalities remain high among hypertensive patients with stable CHD: results of the Dyslipidemia International Study (DYSIS) II Russia

Session Poster Session III - Friday 08:30 - 12:30

Speaker Dominik Lautsch

Congress : EuroPrevent 2015

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Poster Session
  • FP Number : P522

Authors : RG Oganov (Moscow,RU), V Kukharchuk (Moscow,RU), AK Gitt (Ludwigshafen am Rhein,DE), B Ambegaonkar (Whitehouse Station,US), V Ashton (Whitehouse Station,US), M Horack (Ludwigshafen am Rhein,DE), D Lautsch (Wien,AT), P Brudi (Whitehouse Station,US), O Maneshina (Moscow,RU)


RG Oganov1 , V Kukharchuk2 , AK Gitt3 , B Ambegaonkar4 , V Ashton4 , M Horack3 , D Lautsch5 , P Brudi4 , O Maneshina6 , 1State Research Centre for Preventive Medicine - Moscow - Russian Federation , 2Institute of Clinical Cardiology named after A.L. Myasnikov of the Federal State Institution - Moscow - Russian Federation , 3Stiftung Institut fur Herzinfarktforschung - Ludwigshafen am Rhein - Germany , 4Merck Sharp & Dohme Corp. - Whitehouse Station - United States of America , 5MSD - Wien - Austria , 6MSD - Moscow - Russian Federation ,

On behalf: DYSIS II Russia Investigators


Purpose: Despite treatment with lipid lowering therapy (LLT), patients with coronary heart disease (CHD) and hypertension continue to have elevated lipid abnormalities putting them at risk for future cardiovascular events. We aim to identify the prevalence of lipid abnormalities and unmet needs among hypertensive patients with stable CHD in Russia currently on LLT.
Methods: DYSIS II is a multicenter, observational cross-sectional chart review conducted from November 2012-July 2013 in 93 outpatient care centers in Russia. Eligible adult patients had a documented history of CHD (past acute coronary syndrome (ACS) events >3 months before enrollment), full lipid profile available 0-12 months prior to enrollment, on LLT for =3 months or not treated at all, and were not participating in randomized clinical trials involving medication. Patient characteristics, risk factors, treatment patterns, and laboratory values were collected. LDL-C lipid target achievement was assessed based on local guidelines. Patients were identified as having hypertension based on data collected through the study case report form.
Results: Among 567 hypertensive stable CHD patients (74.8% male, mean age 62.5 ± 9.3 years), 95.2% had hypercholesterolaemia, 80.1% history of ACS, 71.9% previous percutaneous coronary intervention or coronary artery bypass graft, 61.6% left ventricular hypertrophy, 53.5% family history of CHD, 40.9% congestive heart failure, and 18.6% type 2 diabetes mellitus. 93.7% (n=531) of patients were on LLT (99.4% statin and 9.2% non-statin), with only 11.3% achieving LDL-C <70 mg/dl. Mean atorvastatin equivalent dose was 21 ± 13 mg/day, 8.7% of treated patients received combination therapy with 2.1% receiving ezetimibe plus statin.
Conclusion: Approximately 89% of LLT treated hypertensive patients with stable CHD in Russia did not achieve the recommended LDL-C target. Additional effective lipid lowering strategies are needed among these very high risk patients to prevent future cardiovascular events.

LLT Treated Patients n=531
Low density lipoprotein (LDL) cholesterol 106.9 ± 35.3 mg/dl
Total cholesterol 178.8 ± 40.8 mg/dl
Triglycerides 141.0 ± 70.3 mg/dl
Non-HDL cholesterol 133.3 ± 39.7 mg/dl

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are